Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - A centrally acting muscle relaxant. Its mode of action is unknown. Chlorphenesin is not available in the United States. (en)
|
http://linked.open...generalReferences
| - # Malley A, Baecher L: Inhibition of histamine and SRS-A from monkey lung tissue by chlorophenesin. J Immunol. 1971 Aug;107(2):586-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4105542 # Kurachi M, Aihara H: Effect of a muscle relaxant, chlorphenesin carbamate, on the spinal neurons of rats. Jpn J Pharmacol. 1984 Sep;36(1):7-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6503049 # Dalessio DJ: Medical treatment of the major neuralgias. Semin Neurol. 1988 Dec;8(4):286-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3074423 (en)
|
http://linked.open...gy/drugbank/group
| - approved (en)
- withdrawn (en)
|
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - Used, along with rest and physical therapy, to treat injuries and other painful muscular conditions. Investigated for use in trigeminal neuralgia (tic douloureux), a neuropathic disorder characterized by severe facial pain. Was investigated as a modulator of histamine release. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - The mechanism of action of chlorphenesin is not well defined, and its effects are measured mainly by subjective responses. It is known that chlorphenesin acts in the central nervous system (CNS) rather than directly on skeletal muscle. (en)
|
http://linked.open.../drugbank/synonym
| - Chlorphenesin (en)
- 3-(4-Chlorophenoxy)-1,2-propanediol (en)
- 3-(P-Chlorophenoxy)-1,2-propanediol (en)
- 3-(P-Chlorophenoxy)propane-1,2-diol (en)
- Chlorphenesinum (en)
- Chlorphénésine (en)
- Clorfenesina (en)
- Glycerol alpha-P-chlorophenyl ether (en)
- P-Chlorophenyl-alpha-glyceryl ether (en)
|
http://linked.open...drugbank/toxicity
| - Symptoms of a chlorphenesin overdose include drowsiness and nausea. (en)
|
http://linked.open.../drugbank/mixture
| |
http://linked.open...ynthesisReference
| - Parker, H.E.; U S . Patent 3,214,336; October 26, 1965; assigned to The Upjohn Company. Collins, R.J. and Matthews, R.J.; US. Patent 3,161,567; December 15, 1964; assigned to The Upjohn Company. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| |
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |